Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer

Martin J. Edelman, David R Gandara, Petr Hausner, Valerie Israel, Donald Thornton, Jennifer DeSanto, L. Austin Doyle

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based upon promising Phase 1 data, a multicenter trial was performed to evaluate the drug in previously treated non-small cell lung cancer (NSCLC). Methods: Patients with Stage IIIb (pleural effusion) or Stage IV NSCLC and performance status 0-1 with adequate organ function who had received at least one and no more than two prior chemotherapy regimens (one of which must have contained a platinum agent) were eligible. Cryptophycin 52 was administered at a dose of 1.5 mg/m2 day 1 and 8 every 3 weeks. Patients were reassessed every two cycles. Results: Twenty-six patients were enrolled of whom 25 are evaluable for toxicity and response. There were no responders, toxicity was predominantly neurologic in the form of peripheral neuropathy and constipation. After the first 12 patients were enrolled, the dose was lowered to 1.125 mg/m2 day 1 and 8. Toxicity was substantially reduced with this maneuver. Median survival was 4.1 months. The median number of cycles was two, however ten patients received four or more courses of therapy. Conclusion: Cryptophycin 52 failed to produce measurable responses utilizing this schedule. In 40% of patients there was evidence of disease stabilization. Toxicity at 1.5 mg/m2 was unacceptable. Since activity and toxicity may be dose and schedule dependent, other schedules of cryptophycin 52 should be considered.

Original languageEnglish (US)
Pages (from-to)197-199
Number of pages3
JournalLung Cancer
Volume39
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

cryptophycin 52
Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Appointments and Schedules
Peripheral Nervous System Diseases
Pleural Effusion
Constipation
Pharmaceutical Preparations
Nervous System
Multicenter Studies

Keywords

  • Clinical trial
  • Cryptophycin 52
  • Non-small cell lung cancer
  • Second line therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. / Edelman, Martin J.; Gandara, David R; Hausner, Petr; Israel, Valerie; Thornton, Donald; DeSanto, Jennifer; Doyle, L. Austin.

In: Lung Cancer, Vol. 39, No. 2, 01.02.2003, p. 197-199.

Research output: Contribution to journalArticle

Edelman, Martin J. ; Gandara, David R ; Hausner, Petr ; Israel, Valerie ; Thornton, Donald ; DeSanto, Jennifer ; Doyle, L. Austin. / Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. In: Lung Cancer. 2003 ; Vol. 39, No. 2. pp. 197-199.
@article{637c4a403a694041b75560b980194de0,
title = "Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer",
abstract = "Background: Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based upon promising Phase 1 data, a multicenter trial was performed to evaluate the drug in previously treated non-small cell lung cancer (NSCLC). Methods: Patients with Stage IIIb (pleural effusion) or Stage IV NSCLC and performance status 0-1 with adequate organ function who had received at least one and no more than two prior chemotherapy regimens (one of which must have contained a platinum agent) were eligible. Cryptophycin 52 was administered at a dose of 1.5 mg/m2 day 1 and 8 every 3 weeks. Patients were reassessed every two cycles. Results: Twenty-six patients were enrolled of whom 25 are evaluable for toxicity and response. There were no responders, toxicity was predominantly neurologic in the form of peripheral neuropathy and constipation. After the first 12 patients were enrolled, the dose was lowered to 1.125 mg/m2 day 1 and 8. Toxicity was substantially reduced with this maneuver. Median survival was 4.1 months. The median number of cycles was two, however ten patients received four or more courses of therapy. Conclusion: Cryptophycin 52 failed to produce measurable responses utilizing this schedule. In 40{\%} of patients there was evidence of disease stabilization. Toxicity at 1.5 mg/m2 was unacceptable. Since activity and toxicity may be dose and schedule dependent, other schedules of cryptophycin 52 should be considered.",
keywords = "Clinical trial, Cryptophycin 52, Non-small cell lung cancer, Second line therapy",
author = "Edelman, {Martin J.} and Gandara, {David R} and Petr Hausner and Valerie Israel and Donald Thornton and Jennifer DeSanto and Doyle, {L. Austin}",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S0169-5002(02)00511-1",
language = "English (US)",
volume = "39",
pages = "197--199",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer

AU - Edelman, Martin J.

AU - Gandara, David R

AU - Hausner, Petr

AU - Israel, Valerie

AU - Thornton, Donald

AU - DeSanto, Jennifer

AU - Doyle, L. Austin

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Background: Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based upon promising Phase 1 data, a multicenter trial was performed to evaluate the drug in previously treated non-small cell lung cancer (NSCLC). Methods: Patients with Stage IIIb (pleural effusion) or Stage IV NSCLC and performance status 0-1 with adequate organ function who had received at least one and no more than two prior chemotherapy regimens (one of which must have contained a platinum agent) were eligible. Cryptophycin 52 was administered at a dose of 1.5 mg/m2 day 1 and 8 every 3 weeks. Patients were reassessed every two cycles. Results: Twenty-six patients were enrolled of whom 25 are evaluable for toxicity and response. There were no responders, toxicity was predominantly neurologic in the form of peripheral neuropathy and constipation. After the first 12 patients were enrolled, the dose was lowered to 1.125 mg/m2 day 1 and 8. Toxicity was substantially reduced with this maneuver. Median survival was 4.1 months. The median number of cycles was two, however ten patients received four or more courses of therapy. Conclusion: Cryptophycin 52 failed to produce measurable responses utilizing this schedule. In 40% of patients there was evidence of disease stabilization. Toxicity at 1.5 mg/m2 was unacceptable. Since activity and toxicity may be dose and schedule dependent, other schedules of cryptophycin 52 should be considered.

AB - Background: Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based upon promising Phase 1 data, a multicenter trial was performed to evaluate the drug in previously treated non-small cell lung cancer (NSCLC). Methods: Patients with Stage IIIb (pleural effusion) or Stage IV NSCLC and performance status 0-1 with adequate organ function who had received at least one and no more than two prior chemotherapy regimens (one of which must have contained a platinum agent) were eligible. Cryptophycin 52 was administered at a dose of 1.5 mg/m2 day 1 and 8 every 3 weeks. Patients were reassessed every two cycles. Results: Twenty-six patients were enrolled of whom 25 are evaluable for toxicity and response. There were no responders, toxicity was predominantly neurologic in the form of peripheral neuropathy and constipation. After the first 12 patients were enrolled, the dose was lowered to 1.125 mg/m2 day 1 and 8. Toxicity was substantially reduced with this maneuver. Median survival was 4.1 months. The median number of cycles was two, however ten patients received four or more courses of therapy. Conclusion: Cryptophycin 52 failed to produce measurable responses utilizing this schedule. In 40% of patients there was evidence of disease stabilization. Toxicity at 1.5 mg/m2 was unacceptable. Since activity and toxicity may be dose and schedule dependent, other schedules of cryptophycin 52 should be considered.

KW - Clinical trial

KW - Cryptophycin 52

KW - Non-small cell lung cancer

KW - Second line therapy

UR - http://www.scopus.com/inward/record.url?scp=0037316411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037316411&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(02)00511-1

DO - 10.1016/S0169-5002(02)00511-1

M3 - Article

VL - 39

SP - 197

EP - 199

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -